Inactive Instrument
Kalytera Therapeutics Inc Stock Toronto S.E.
Stocks
CA48349P1036
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.85M 3.33M 3.12M 2.85M 367M 5.45M 36.55M 14.34M 184M 14.46M 14.15M 612M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.51M 3.91M 3.65M 3.34M 430M 6.39M 42.82M 16.8M 215M 16.94M 16.57M 717M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | -10.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 2017-06-20 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 2018-06-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 2021-03-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.00% | -23.08% | - | - | 37 | |
| +1.29% | +3.46% | +7.10% | +16.36% | 49.47B | |
| +0.21% | +12.90% | +493.60% | +590.98% | 43.97B | |
| +3.51% | +14.00% | +23.45% | +80.73% | 39.6B | |
| +1.47% | +3.32% | +33.88% | +8.71% | 39.29B | |
| +0.85% | +7.66% | +21.22% | +48.78% | 32.43B | |
| -1.46% | +4.30% | - | - | 16.84B | |
| +1.10% | +3.96% | +32.51% | +122.68% | 16.49B | |
| +0.34% | +3.40% | +5.70% | +18.79% | 14.01B | |
| +1.00% | +16.87% | +81.17% | +23.99% | 12.77B | |
| Average | -0.25% | +6.18% | +87.33% | +113.88% | 29.43B | |
| Weighted average by Cap. | +1.03% | +5.95% | +107.47% | +139.13% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.22M -13.18M -12.32M -11.26M -1.45B -21.54M -144M -56.67M -726M -57.15M -55.91M -2.42B | 4.21M 3.02M 2.62M 2.44M 2.23M 288M 4.28M 28.66M 11.25M 144M 11.34M 11.1M 480M |
| Net Debt | 704K 505K 437K 409K 374K 48.18M 715K 4.79M 1.88M 24.1M 1.9M 1.86M 80.28M | 920K 660K 571K 534K 488K 62.96M 934K 6.26M 2.46M 31.5M 2.48M 2.42M 105M |
Employees
-
